Therapy of Mantle Cell Lymphoma: New Treatment Options in an Old Disease or Vice Versa?

Seminars in Hematology

Volumn 48, Issue 3, 2011, Pages 145-147

  Dreyling, Martin ^a  

^a LUDWIG MAXIMILIANS UNIVERSITY   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

B LYMPHOCYTE RECEPTOR; BENDAMUSTINE; CYCLIN D1; CYCLOPHOSPHAMIDE; CYTARABINE; DEXAMETHASONE; DOXORUBICIN; RITUXIMAB; TEMSIROLIMUS; VINCRISTINE;

AUTOLOGOUS HEMATOPOIETIC STEM CELL TRANSPLANTATION; CANCER CLASSIFICATION; CANCER IMMUNOTHERAPY; CHROMOSOME TRANSLOCATION; DIAGNOSTIC ACCURACY; DISEASE COURSE; DRUG MEGADOSE; EDITORIAL; HUMAN; MANTLE CELL LYMPHOMA; MOLECULAR PATHOLOGY; OVERALL SURVIVAL; PRIORITY JOURNAL; RISK ASSESSMENT; TREATMENT INDICATION;

HUMANS; LYMPHOMA, MANTLE-CELL; MOLECULAR TARGETED THERAPY;

EID: 79960510971     PISSN: 00371963     EISSN: 15328686     Source Type: Journal    
DOI: 10.1053/j.seminhematol.2011.06.003     Document Type: Editorial

References (11)

1. Gérard-Marchant R., Hamlin I., Lennert K., et al. Classification of non-Hodgkin's lymphomas [letter]. Lancet 1974, 2:405-408.
2. Jares P., Colomer D., Campo E. Genetic and molecular pathogenesis of mantle cell lymphoma: perspectives for new targeted therapeutics. Nat Rev Cancer 2007, 7:750-762.
3. Dreyling M., Hiddemann W. Current treatment standards and emerging strategies in mantle cell lymphoma. American Society of Hematology Education Program Book Hematology 2009, 542-554.
4. Fernandez V., Salamero O., Espinet B., et al. Genomic and gene expression profiling defines indolent forms of mantle cell lymphoma. Cancer Res 2010, 70:1408-1418.
5. Hoster E., Dreyling M., Klapper W., et al. A new prognostic index (MIPI) for patients with advanced stage mantle cell lymphoma. Blood 2008, 111:558-565.
6. Hoster E., Metzner B., Forstpointner R., et al. Autologous stem cell transplantation and addition of rituximab independently prolong response duration in advanced stage mantle cell lymphoma [abstract 880]. Blood 2009, 114.
7. Hermine O., Hoster E., Walewski J., et al. Alternating Courses of 3x CHOP and 3x DHAP plus rituximab followed by a high dose ARA-C containing myeloablative regimen and autologous stem cell transplantation (ASCT) is superior to 6 courses CHOP plus rituximab followed by myeloablative radiochemotherapy and ASCT in mantle cell lymphoma: results of the MCL Younger Trial of the European Mantle Cell Lymphoma Network (MCL net) [abstract 110]. Blood 2010, 116.
8. Kluin-Nelemans J., Hoster E., Vehling-Kaiser U., et al. Rituximab maintenance significantly prolongs duration of remission in elderly patients with mantle cell lymphoma [abstract 50]. Haematologica (16th EHA Congress) 2011, 96(Suppl 2).
9. Hess G., Herbrecht R., Romaguera J., et al. Phase III study to evaluate temsirolimus compared with investigator's choice therapy for the treatment of relapsed or refractory mantle cell lymphoma. J Clin Oncol 2009, 27:3822-3829.
10. Kahl B, Byrd JC, Flinn I, et al. Clinical safety and activity in a phase 1 study of CAL-101, an isoform-selective inhibitor of phosphatidylinositol 3-kinase P110δ in patients with relapsed or refractory non-Hodgkin lymphoma [abstract 1777]. 52nd ASH Meeting, December 2010; Orlando, FL.
11. Fowler N, Sharman JP, Smith SM, et al. The Btk inhibitor, PCI-32765, induces durable responses with minimal toxicity in patients with relapsed/refractory B-cell malignancies: results from a phase I study [abstract 964]. 52nd ASH Meeting, December 2010; Orlando, FL.